We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Implantable Device Could Save Diabetes Patients from Dangerously Low Blood Sugar

By HospiMedica International staff writers
Posted on 11 Jul 2025

For individuals with Type 1 diabetes, hypoglycemia (low blood sugar) presents a life-threatening threat, particularly when glucose levels drop too low, which can result in seizures, coma, or even death. More...

While glucagon injections are commonly used to reverse these dangerous drops in blood sugar, many patients—especially children or those who are asleep—may not realize their blood sugar is falling to dangerous levels. Standard procedures are not always effective in these situations, which often leads to delays in treatment and poses a substantial risk to patient health. Now, researchers have developed an implantable device that can automatically release glucagon when blood sugar levels become dangerously low, offering a potential solution for better management of hypoglycemia.

This implantable device, developed by engineers from the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA), releases glucagon automatically when blood sugar levels fall too low. The device consists of a small drug reservoir implanted under the skin, capable of delivering glucagon or epinephrine in response to signals from a glucose monitor or the patient's own action. This innovative system works by using a shape-memory alloy, which changes its shape when heated, to release the drug. The reservoir contains a powdered form of glucagon, which remains stable and ready for use, and the system can be triggered either by a manual signal or automatically when blood sugar drops below a certain threshold.

The device was tested in diabetic mice, and the results, published in Nature Biomedical Engineering, showed that it could effectively prevent hypoglycemia by releasing glucagon within 10 minutes of activation, stabilizing blood sugar levels. The system’s ability to function without requiring pre-processing or complex steps makes it a potential game-changer for diabetes care. The researchers are currently working on extending the device’s lifespan for long-term use in humans. Future studies will focus on refining the device for human clinical trials and enhancing its usability in real-world conditions.

“This is a small, emergency-event device that can be placed under the skin, where it is ready to act if the patient’s blood sugar drops too low,” said MIT’s Daniel Anderson, senior author of the study. “Our goal was to build a device that is always ready to protect patients from low blood sugar. We think this can also help relieve the fear of hypoglycemia that many patients, and their parents, suffer from.”

Related Links:
MIT


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
Syringe Pump
SP50 Series
X-Ray Generator
Advantage Plus Generators
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.